Innovation Kyoto 2016 Investment Limited Partnership ("KYOTO-icap No.1 Fund"), with Kyoto University Innovation Capital Corporation ("Kyoto iCAP") (Head Office: Sakyo-ku, Kyoto; Representative Director: Kimi Kusumi) as unlimited liability partner, has made an additional investment in Luxonus Inc. (Head office: Minato-ku, Tokyo; Representative Director: Sadakazu Aiso).

Outline of this investment
　Luxonus is a venture company that aims to commercialize a new imaging device based on photoacoustic imaging technology (Photo Acoustic Imaging = PAI). The research results that formed the basis of the company's establishment have been supported by the "Kyoto University-Canon Project" (conducted from FY2006 to FY2015), a joint research project between Kyoto University and Canon Inc. and by the Innovative R&D Promotion Program (ImPACT) of the Japan Science and Technology Agency's "Innovative Visualization The project was created through the "Creation of New Growth Industries through Innovative Visualization Technology" (implemented from FY2014 to FY2018) of the Japan Science and Technology Agency's Innovative R&D Promotion Program (ImPACT).

　PAI is a technology that supplements ultrasound waves generated by pulsed light irradiation of a living body with a specially shaped sensor and converts the received data into images by computer. Compared to existing imaging technologies such as ultrasound, X-ray computed tomography (CT), and nuclear magnetic resonance imaging (MRI), PAI is characterized by its ability to perform real-time 3D imaging with ultra-high resolution (0.2 mm) without exposure or invasiveness (no contrast agent is used).

　Another advantage of PAI is its ability to measure the oxygen saturation distribution of blood flow, and having received regulatory approval as a medical device in September 2022, its sales are expected to expand as a diagnostic imaging device for diseases such as breast cancer, lymphedema, peripheral arteriovenous disease, and skin diseases.

　Kyoto iCAP highly evaluated the superiority of the PAI imaging device as a medical device and Luxonus' R&D capabilities in achieving regulatory approval on schedule with the original plan, and decided to underwrite 100 million yen of the total 230 million yen raised through preferred shares. ITFARM Corporation, KSP Corporation, and Future Venture Capital Inc. also participated in this procurement round.

Luxonus Inc.　summary
Established December 2018
Business Description Research and development of medical diagnostic equipment based on photoacoustic 3D imaging (PAI) technology
Head office location Minato-ku, Tokyo
Representative Director Sadakazu Aiso
HP:https://www.luxonus.jp/

About Kyoto University Innovation Capital Corporation (Kyoto iCAP)
　As a wholly-owned subsidiary of Kyoto University, KYOTO-iCAP provides investment and other business support to companies that utilize research results generated by Kyoto University and other national universities. We currently operate the KYOTO-iCAP No. 1 Fund (established in January 2016) with a total value of 16 billion yen and the Innovation Kyoto 2021 Investment Limited Partnership ("KYOTO-iCAP No. 2 Fund") (established in January 2021) with a total value of 18 billion yen. The KYOTO-iCAP No. 1 Fund has a maturity of up to 20 years, and the KYOTO-iCAP No. 2 Fund has a maturity of up to 17 years, making it possible to provide long-term support for the practical application of research results from Kyoto University, which has strengths in basic research. The KYOTO-iCAP 2 Fund has a maximum maturity of 17 years. In addition, KYOTO-iCAP No. 2 Fund will invest a portion of the funds in ventures originating from national universities other than Kyoto University.

Contact information for inquiries
Kyoto University Innovation Capital Co., Ltd.
36-1 Yoshida Honmachi, Sakyo-ku, Kyoto 606-8317, Japan
Osami Kono, Senior Officer, Business Development Department
TEL: 075-753-7588 FAX: 075-753-7592
E-mail: info@kyoto-unicap.co.jp